COVID-19 Drug Delivery Devices Market (2024 - 2030)

Market Size & Trends

The global COVID-19 drug delivery devices market size was valued at USD 1.68 billion in 2023 and is expected to witness a decline with a CAGR of (0.4%) from 2024 to 2030. The COVID-19 pandemic underscored the need for efficient drug delivery systems to ensure that vaccines and therapeutics are administered safely and effectively. This has led to increased investments in developing and producing advanced drug-delivery devices, such as self-injectable systems, inhalers, and wearable devices. In addition, the market was stimulated by the competitive race among healthcare companies and increased effective drug development.

The pandemic highlighted the vulnerability of individuals with pre-existing conditions, driving the demand for drug delivery devices that can manage chronic illnesses more effectively. This includes devices that offer controlled and sustained release of medications, improving patient outcomes. In addition, the pandemic has accelerated the shift towards home-based care, with patients increasingly preferring treatments in the comfort of their homes to avoid hospital visits. This trend has boosted the demand for user-friendly drug delivery devices that patients or caregivers can easily operate.

Moreover, technological advancements in drug delivery technologies, such as microneedles and implantable devices, have enhanced the precision and efficiency of drug administration. These advancements improve the efficacy of treatments and reduce the risk of side effects, making them more appealing to healthcare providers and patients.

Product Insights

Prefilled syringes accounted for the largest market share of 43.3% in 2023, owing to the increased demand for efficient and safe vaccine administration. Pre-filled syringes offer a convenient and reliable method for delivering vaccines, reducing the risk of contamination and dosing errors. In addition, patients with chronic conditions such as diabetes and autoimmune diseases require regular medication, and pre-filled syringes provide a user-friendly solution that enhances patient compliance and adherence to treatment regimens. Market participants such as Johnson & Johnson Services, Inc. and Serum Institute of India Pvt. Ltd. have introduced innovations in syringe design, with the development of single-chamber and dual-chamber pre-filled syringes, improving medication stability and shelf-life. In addition, integrating smart technologies, such as connected devices that can monitor and record administration data, has further enhanced the appeal of pre-filled syringes.

Patches are projected to grow at a CAGR of 5.0% during the forecast period due to the increased demand for non-invasive and user-friendly drug delivery methods. Products such as microneedle patches offer a convenient and painless alternative to traditional injection-based methods, which makes them particularly appealing for vaccine administration and chronic disease management. Moreover, the shift towards home-based healthcare, with more patients opting for home treatment, has led to the demand for easy-to-use and reliable drug delivery systems. Patches meet this need by offering a ready-to-use solution that simplifies the administration process, making it easier for patients to manage their treatments at home.

Route Of Administration Insights

The parenteral segment secured the dominant market share of 37.1% in 2023 owing to the increased need for rapid and effective vaccine deployment. Parenteral administration, which includes intravenous, intramuscular, and subcutaneous injections, ensures that vaccines and therapeutics are delivered directly into the bloodstream, providing a quick onset of action and high bioavailability. Innovations in parenteral drug delivery devices, such as auto-injectors and pre-filled syringes, have improved the safety, accuracy, and ease of administration. These devices are designed to minimize dosing errors and reduce the risk of contamination and are highly reliable for mass vaccination campaigns.

The nasal route of administration is expected to boost as the fastest-growing segment over the forecast period due to the increased demand for non-invasive and user-friendly drug delivery methods. Nasal drug delivery offers a convenient and painless alternative to injection. This ease of use is crucial in COVID-19, where rapid and widespread vaccination and treatment are essential. Moreover, innovations such as nasal sprays and dry powder formulations have enhanced the efficiency and effectiveness of drug delivery. These advancements ensure that medications are absorbed quickly and directly into the bloodstream, bypassing the gastrointestinal tract and first-pass metabolism, which can degrade the drug.

Distribution Channel Insights

Hospital pharmacies held the dominant market share in 2023 pertaining to the rise in chronic diseases and comorbidities among COVID-19 patients and hospitalizations. Hospital pharmacies have been at the forefront of managing the pandemic, necessitating a continuous supply of drug delivery devices for administering vaccines, antiviral drugs, and supportive treatments.

Online pharmacies are anticipated to grow at a CAGR of 8.0% over the forecast period due to the surging adoption of contactless and convenient medication access. The COVID-19 pandemic has heightened the need for urgent medications, making online pharmacies an attractive option for patients seeking timely medical deliveries. Moreover, technological advancements in e-commerce, secure payment systems, and telemedicine have made it easier for patients to order medications and drug delivery devices online.

Regional Insights

The North America COVID-19 drug delivery devices market dominated the global market with a revenue share of 52.7% in 2023 with the high demand for efficient and safe vaccine administration. The region has witnessed significant investments in developing and distributing advanced drug delivery devices to ensure rapid and effective vaccination. This includes innovations in pre-filled syringes, auto-injectors, and wearable devices that enhance the efficiency and safety of vaccine delivery.

U.S. COVID-19 Drug Delivery Devices Market Trends

The COVID-19 drug delivery devices market in the U.S. was driven by the country’s well-established healthcare infrastructure and the presence of a large number of key pharmaceutical companies. These companies have heavily invested in technological advancements such as smart drug delivery systems and connected devices that improve the precision and monitoring of drug administration. These technologies enhance patient compliance and provide valuable data for healthcare providers to optimize treatment protocols.

Europe COVID-19 Drug Delivery Devices Market Trends

The COVID-19 drug delivery devices market in Europe held a significant market share of the global market in 2023 as regional governments provided substantial funding for developing and distributing COVID-19 vaccines and related drug delivery devices. This financial support encouraged pharmaceutical companies to invest in innovative drug delivery technologies, further boosting the market growth.

Asia Pacific COVID-19 Drug Delivery Devices Market Trends

The COVID-19 drug delivery devices market in the Asia Pacific region registered a substantial market share in 2023 owing to the rising prevalence of chronic diseases. Patients with chronic conditions, including respiratory disorders and cardiac complications, require regular medication, and advanced drug delivery systems offer a more convenient and effective way to manage these conditions. This has increased the adoption of insulin pumps, inhalers, and transdermal patches. In addition, with more patients opting for home treatment to avoid hospital visits, the demand for self-injectors and wearable infusion pumps has surged.

Key COVID-19 Drug Delivery Devices Company Insights

Some of the key market players operating in the COVID-19 drug delivery devices market are such AstraZeneca, Johnson & Johnson Services, Inc., and Serum Institute of India Pvt. Ltd., among others. These companies focused on launching new and advanced products and boosting their production capacities.

• AstraZeneca is a British-Swedish biotechnology and pharmaceutical company that focuses on developing prescription medicines to treat diseases related to cardiovascular, oncology, respiratory, immunology, and renal & metabolism areas. AstraZeneca is also known for its significant role in developing the Oxford-AstraZeneca COVID-19 vaccine.

• Serum Institute of India (SII) offers a wide range of vaccines for diseases such as polio, diphtheria, tetanus, pertussis, Hib, BCG, hepatitis B, measles, mumps, rubella, and pneumococcal infections. The company gained international recognition for its role in producing the Covishield vaccine, developed in collaboration with AstraZeneca and Oxford University, to combat COVID-19.

Recent Developments

• In May 2023, Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) approval of their PAXLOVID (nirmatrelvir tablets and ritonavir tablets) for treating mild-to-moderate COVID-19 in adults at high risk of progressing to severe illness, including hospitalization or death.

COVID-19 Drug Delivery Devices Market